CNX Therapeutics appoints Erin Federman as non-executive director

London, England – Wednesday 4 March 2026: CNX Therapeutics Limited ("CNX Therapeutics"), a European specialty pharmaceutical company, today announced the appointment of Erin Federman as a non-executive director, with effect from 1 March 2026.

Erin brings over two decades of experience in global commercial strategy across pharma, biotech and private equity-backed life sciences environments, having held senior roles at STADA, Novo Nordisk and Mylan. She currently works as a strategic advisor and non-executive board member across the life sciences sector.

"We are delighted to welcome Erin to the CNX board at what is an exciting new chapter for the company," said Guy Clark, CEO of CNX Therapeutics. "With Inflexion's continuation fund behind us and a growing portfolio across Europe, our ambition has never been clearer. Erin's depth of experience in commercial strategy, market entry and building high-performing organisations in complex international markets makes her exactly the right person to support us as we scale.”

"What stands out about CNX is the combination of genuine commercial ambition and a real commitment to patients - not many businesses hold both with equal conviction," said Erin Federman. "As a B Corp-certified company with a growing European footprint, CNX is exactly the kind of business I want to be part of, and I look forward to contributing at board level as that growth continues."

CNX Therapeutics was acquired by Inflexion Private Equity, a leading mid-market private equity firm, in 2021, and was selected as one of four high-performing portfolio companies for Inflexion's £2.3bn continuation fund in 2025.